Quantification of protein markers monitoring the pre-analytical effect of blood storage time before plasma isolation using ¹⁵ N metabolically labeled recombinant proteins.

Ahn HS, Park SJ, Jung HG, Woo SJ, Lee C

Journal of mass spectrometry : JMS1 Dec 2018Cited by 1 (Europe PMC)

PMID30251292DOI10.1002/jms.4294PepBankPUB-30251292

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

01HumanNot a test of Thymosin beta-4 (human) aloneOther designOther
In 40 clinical plasma samples, thymosin beta‑4 (TMSB4X) was higher when blood was kept overnight at 4 C than when plasma was prepared within a day.
In plain wordsIn patient samples, thymosin beta‑4 in plasma was higher when blood stood overnight than when plasma was prepared within a day.
Peptide
Thymosin beta-4 (human)
Outcome
IncreasePlasma TMSB4X in clinical samples kept overnight at 4 C
Study
n = 40
Outcome group
Endogenous peptide levels · Whole body
Measurements
TMSB4X mean level, plasma prepared within a day
0.98 μg/mL
40 clinical samples
TMSB4X mean level, blood kept overnight at 4°C
5.36 μg/mL
40 clinical samples
Source sentences
Summary
Compared with the plasma samples prepared within a day, the level of both PFN1 and TMSB4X increased in the plasma samples prepared from the blood collected the day before and kept overnight at 4°C (0.51 to 3.11 μg/mL for PFN1 and 0.98 to 5.36 μg/mL for TMSB4X in average).
1 context sentence(design, population, supporting numbers)
Summary · context
We further monitored PFN1 and TMSB4X on 40 samples collected for protein diagnostics under a typical clinical study condition.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3025129203
02HumanNot a test of Thymosin beta-4 (human) aloneOther designOther
In plasma samples, the amount of thymosin beta‑4 (TMSB4X) increased rapidly with longer storage time of whole blood before plasma preparation.
In plain wordsThymosin beta‑4 measured in blood plasma rose quickly when blood stood longer before plasma was prepared.
Peptide
Thymosin beta-4 (human)
Outcome
IncreasePlasma TMSB4X amount versus storage time before plasma preparation
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Whole body
Source sentences
Summary
The amounts of PFN1 and TMSB4X increased rapidly depending on the storage time between blood collection and plasma preparation.
1 context sentence(design, population, supporting numbers)
Summary · context
In order to account such pre-analytical effects, we performed liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM-MS) on 15 selected proteins in plasma samples prepared by varying storage time and temperature of whole blood prior to plasma isolation.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3025129201
03HumanNot a test of Thymosin beta-4 (human) aloneOther designOther
Relative quantification showed a significant difference (P < 0.05) in thymosin beta‑4 (TMSB4X) among five proteins with varied blood storage.
In plain wordsThymosin beta‑4 was one of five blood proteins that differed significantly with blood storage conditions.
Peptide
Thymosin beta-4 (human)
Outcome
Direction not reportedRelative plasma TMSB4X difference with storage
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Whole body
Source sentences
Summary
Relative quantification further revealed that five proteins including PFN1, S10A8, S10A9, S10A11, and TMSB4X showed significant difference (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In order to account such pre-analytical effects, we performed liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM-MS) on 15 selected proteins in plasma samples prepared by varying storage time and temperature of whole blood prior to plasma isolation.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3025129202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.